Search | VHL Regional Portal

Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs.

Lotia Farrukh, Ismat; Lachenal, Nathalie; Adenov, Malik M; Ahmed, Saman; Algozhin, Yerkebulan; Coutisson, Sylvine; Garavito, Epifanio Sánchez; Hewison, Catherine; Holtzman, David; Huerga, Helena; Janmohamed, Aleeza; Khan, Palwasha Y; Jacques, Gamarly Leblanc; Lomtadze, Nino; Melikyan, Nara; Mitnick, Carole D; Mussabekova, Gulnaz; Osso, Elna; Perea, Sara; Putri, Fauziah Asnely; Rashidov, Mahmud; Rich, Michael L; Sakhabutdinova, Yekaterina; Seung, Kwonjune J; Stambekova, Assel; Vásquez, Dante Vargas; Franke, Molly F; Khan, Uzma.

Clin Infect Dis ; 78(1): 144-148, 2024 01 25.

Article in English | MEDLINE | ID: mdl-37606512

ABSTRACT

Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of 31 continued pregnancies, 81% had live births with no reported malformations, and 68% of neonates had normal birth weights. Effective MDR/RR-TB treatment during pregnancy can improve maternal outcomes without harming neonates.

Subject(s)

Antitubercular Agents , Tuberculosis, Multidrug-Resistant , Infant, Newborn , Humans , Female , Pregnancy , Antitubercular Agents/therapeutic use , Tuberculosis, Multidrug-Resistant/drug therapy , Diarylquinolines/therapeutic use , Treatment Outcome , Clinical Protocols , Live Birth

ABSTRACT

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL